Vivek Subbiah: Oncogenic KRAS is a Hallmark of Pancreatic Cancer
Vivek Subbiah, Chief, Early-Phase Drug Development at Sarah Cannon Research Institute, shared on LinkedIn about a recent paper by Emily L. Lasse Opsahl et al. published on AACR Journals:
“Oncogenic KRAS is a hallmark of pancreatic cancer, one of the deadliest malignancies, and inhibition of oncogenic KRAS alone is, in most patients, not sufficient to eradicate the tumor.
Drugging KRAS is one of the hottest topics in oncology.
The two studies published in Cancer Discovery by Stanger and colleagues and Lowe and colleagues propose combination therapy approaches to leverage the power of the immune system, together with KRAS inhibition, to achieve long-term remission.”
Title: Two Shots on Goal: Combination of RAS Inhibition and Immunotherapy Drives Long-term Remission in Pancreatic Cancer
Authors: Emily L. Lasse Opsahl, Marina Pasca di Magliano
See more articles about Vivek Subbiah.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023